SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001193125-21-160519
Filing Date
2021-05-13
Accepted
2021-05-13 16:21:10
Documents
61
Period of Report
2021-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q d155579d10q.htm   iXBRL 10-Q 1371259
2 EX-31.1 d155579dex311.htm EX-31.1 6693
3 EX-31.2 d155579dex312.htm EX-31.2 6687
4 EX-32.1 d155579dex321.htm EX-32.1 6352
10 GRAPHIC g155579g25t34.jpg GRAPHIC 162570
  Complete submission text file 0001193125-21-160519.txt   4664559

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA sbtx-20210331.xsd EX-101.SCH 31898
6 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE sbtx-20210331_cal.xml EX-101.CAL 25820
7 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE sbtx-20210331_def.xml EX-101.DEF 114770
8 XBRL TAXONOMY EXTENSION LABEL LINKBASE sbtx-20210331_lab.xml EX-101.LAB 264105
9 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE sbtx-20210331_pre.xml EX-101.PRE 214850
11 EXTRACTED XBRL INSTANCE DOCUMENT d155579d10q_htm.xml XML 461424
Mailing Address 500 FAIRVIEW AVENUE NORTH, SUITE 600 SEATTLE WA 98109
Business Address 500 FAIRVIEW AVENUE NORTH, SUITE 600 SEATTLE WA 98109 206-456-2900
Silverback Therapeutics, Inc. (Filer) CIK: 0001671858 (see all company filings)

IRS No.: 811489190 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-39756 | Film No.: 21919954
SIC: 2834 Pharmaceutical Preparations